Idenix Pharmaceuticals, Inc. Sustainability Profile
Idenix Pharmaceuticals, Inc., a prominent player in the biotechnology sector, is headquartered in the United States. Founded in 1998, the company has made significant strides in the development of innovative therapies, particularly in the field of antiviral treatments. Idenix focuses on addressing unmet medical needs in the treatment of hepatitis C and other viral infections, leveraging its expertise in drug discovery and development. With a robust pipeline of core products, Idenix is recognised for its unique approach to creating effective and safe therapies. The company has achieved notable milestones, including advancements in clinical trials that have positioned it as a leader in the antiviral market. Idenix Pharmaceuticals continues to enhance its market position through strategic partnerships and a commitment to scientific excellence, making it a key contributor to the global healthcare landscape.
DitchCarbon Score
How does Idenix Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Idenix Pharmaceuticals, Inc.'s score of 72 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Idenix Pharmaceuticals, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Merck & Co., Inc., and therefore, any climate commitments or reduction targets may be influenced by Merck's initiatives. As a subsidiary, Idenix Pharmaceuticals may align with Merck's sustainability goals, which include commitments to reduce greenhouse gas emissions across their operations. However, specific reduction targets or achievements for Idenix are not detailed in the available data. Idenix Pharmaceuticals has not disclosed any specific climate pledges or initiatives independently. The absence of emissions data and reduction targets suggests that the company may rely on the broader corporate strategies set forth by its parent company, Merck & Co., Inc., which is known for its commitment to sustainability and climate action. In summary, while Idenix Pharmaceuticals does not provide specific emissions data or reduction targets, it is positioned within a corporate family that prioritises climate commitments through Merck's established sustainability framework.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 1,532,400,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 5,760,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Idenix Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Idenix Pharmaceuticals, Inc.'s Location?
Idenix Pharmaceuticals, Inc.'s Scope 3 Categories Breakdown
Idenix Pharmaceuticals, Inc.'s Scope 3 emissions, which increased by 3% last year and increased by approximately 5% since 2014, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 78% of Scope 3 emissions.
Top Scope 3 Categories
Idenix Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Idenix Pharmaceuticals, Inc. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
